Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Cybin (NYSE American: CYBN) announced that Chief Medical Officer Amir Inamdar will participate in a panel at the 2025 Milken Institute Future of Health Summit in Washington, D.C., held November 4–6, 2025.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

- Chief Medical Officer Amir Inamdar to participate in a panel on November 5, 2025 -

TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (”Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery systems, today announced that Amir Inamdar, Cybin’s Chief Medical Officer, will participate in a panel at the 2025 Milken Institute Future of Health Summit, taking place November 4-6, 2025, in Washington, D.C. The panel details are as follows:

Panel title: Reimagining Mental Health: Innovation at the Intersection of Care and Technology
Date: Wednesday, November 5, 2025
Time: 2:00 – 3:00 PM ET

To access the live panel discussion, please click here. The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page.

About Cybin

Cybin is a breakthrough Phase 3 clinical-stage neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.

With promising class leading data, Cybin is working to change the mental health treatment landscape through the introduction of novel drugs that provide effective and durable results for patients. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds.

Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, and Ireland.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251103373566/en/

Investor Contact:
Josh Barer
astr partners
Managing Director
(908) 578-6478
josh.barer@astrpartners.com

George Tziras
Chief Business Officer
Cybin Inc.
1-866-292-4601
irteam@cybin.com – or – media@cybin.com

Source: Cybin Inc.